Phico Therapeutics has announced the appointment of Andrew Armour as its new Financial Director, along with Professor Mark Wilcox and David Beadle as non-executive directors.
The appointments have been made to support the progression of Phico’s lead product SASPject through clinical trials, and the financing of the Company’s planned clinical-grade manufacturing facility.
Andrew Armour is a chartered accountant with experience in the healthcare industry, particularly in financial restructuring, equity fundraising and corporate acquisitions and disposals. He previously held positions at Grant Thornton and Deloitte, working on restructuring and corporate finance assignments, before becoming the FD of Colchester Hospital.
Prof Mark Wilcox has held several positions at the Leeds Teaching Hospitals and is currently a consultant microbiologist and head of research and development in microbiology, and professor of medical microbiology at the University of Leeds. He has a wealth of clinical experience in infectious diseases and advises Public Health England and NHS England on diagnosis, prevention and development of infection prevention and control products and new antimicrobial agents to target healthcare associated infections.
David Beadle has over 25 years’ experience within healthcare and finance, having worked in marketing and strategic development at Schwarz Pharma and Schering AG before moving into investment banking, where he built and led highly ranked healthcare equity research teams both globally and across Europe for over ten years. He is specialised in consulting on scientific, corporate finance and business development strategies within the healthcare and biotechnology space. David joins Phico as a non-executive director and will primarily advise on strategies for business development.